U.S. Markets open in 8 hrs 20 mins

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.85-0.80 (-21.92%)
At close: 4:00PM EDT
People also watch
  • Bought some more on the drop today. Being Friday, and the chance of either another patient enrollment or a conversion announcement next week, I thought why not.
  • shorting this a year ago made sense. shorting it now with possible approval in the next six months just foolish. this will continue higher in next few months.
  • Classic strangle collar on the PPS trading with large buy quantity of more than 30,000 shares yet only 100 share trades actually trading every couple of seconds. Manipulators at work to accumulate at a low price based on gains in PPS anticipated after they are done accumulating. Indicators from trading earlier this week through yesterday support this strategy. Good time for the non-trading long term value holders to pick up some more shares at a bargain price.
  • Anybody like to venture a guess as to the identity of the scammer manipulators who are so determined to suppress the NVIV share price, and why? Incredible to see a 23% fall like this on no news after a nice climb out of the deep cellar. They ought to be turned in to the SEC and put behind bars. Unfortunately, these days the SEC and the FDA are toothless phantom agencies run by pawns of the investment banks and big pharma, respectively, both of which are busy robbing us blind, with Trump's blessing. No regulation and you can kiss your money goodbye!
  • Continuation should continue into the 4s with ease. This has been way too low for way too long
  • Don't know if this stock is going up due to IBB. Perhaps JMP presentation?
  • NVIV will be bought right after FDA approval news. my guess is they will seek $15-20 range. price moves up to 10 before end of the year
  • only up 5% so far today ...I am a little disappointed
  • If ICPT (Intercept Pharmaceuticals) was worth +$400 pps (2014) for a drug for primary biliary cirrhosis (PBC is a relatively rare disease, affecting up to 1 in 3–4,000 people) why wouldn't NVIV not be worth a similar valuation as its also providing a treatment for something that essentially has no effective treatment (spinal cord injury)?
  • i think we just have to hold on patient enrollment is almost done we just have to hang in there
  • NEWS---Our CEO did a good job on the presentation today. Went through it at the right speed, no stammering or repeats, sounded confident, positive and motivated. Even with the same old slightly modified slide show he stayed on point and clear.
    I'm guessing he must have been rested and practiced. This was the best of all the show and tell sessions I have witnessed. Good Job Mark.
  • Congratulations to Allegheny Hospital for your support of medical history and being an ACTIVE participant in the INSPIRE study. For the last 2 weeks we've featured what appears to be "slackers" in the study. Population centers higher than most, who are elisted, yet have produced nothing in terms of new patients. Your participation is greatly appreciated, and illustrates your committment toward birthing a new SOC for these kinds of injuries. That alone offers more hope to the injured than anything else that has broached this realm of medical care. Congrats to the Allegheny team, the patient, and also to Invivo for getting to 16/20. Only four more to go to complete INSPIRE and then it is on to pure evaluation of the six month intervals for these patients and subbition of the data, already very compelling toward justifying approval.
  • For a lift go to Jesi's FB page. She is standing, happy and looking very strong. She says she is improving daily. Her implant was 2 years ago and she he was very badly injured.
  • I believe I've asked the following question before: anyone have an idea of why invivo hasn't updated Jesi's progress?
  • My guess is this is a very well funded short squeeze and it's making them squeal....
  • Hey, no good reason why this stock is not above $8, much less $6, much less a measly $4, which it was stuck at very recently and was still undervalued. Can we at least get back to $4 with just 4 patients left to enroll?
  • Something is cooking. Possibly good news on the way
  • IMO nobody should be selling shares of NVIV today.
  • It's amazing so many are stumped as to the reason for the rise this week.

    1) The healthcare sector has had the largest one week/one month rally since the summer of 2014. All ships rise with the tide...

    2) Today is the last day of the Russell Rebalancing. The transaction of Invivo shares being sold from this index were likely completed earlier in the week/late last week - meaning less selling pressure

    3) From a chart TA standpoint, $2 bucks held as support until NVIV broke out from under its downtrend line